Showing results (171-180 of 238) with videos related to

Sort By:
Pageof 24
American Journal of Hematology|June 16, 2018
Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experienceChezi Ganzel, Zhuoxin Sun, Larry D Cripe, et al.
Cancer Discovery|October 29, 2021
Intracellular Cholesterol Pools Regulate Oncogenic Signaling and Epigenetic Circuitries in Early T-cell Precursor Acute Lymphoblastic LeukemiaMarissa Rashkovan, Robert Albero, Francesca Gianni, et al.
Blood|August 2, 2011
Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997Mitchell R Smith, Donna Neuberg, Ian W Flinn, et al.
Haematologica|September 3, 2016
International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemiaNicola Gökbuget, Hervè Dombret, Jose-Maria Ribera, et al.
Cancer|May 15, 2023
Obesity in adult acute myeloid leukemia is not associated with inferior response or survival even when dose capping anthracyclines: An ECOG-ACRIN analysisJames M Foran, Zhuoxin Sun, Catherine Lai, et al.
Leukemia Research|November 13, 2021
Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trialSelina M Luger, Victoria X Wang, Jacob M Rowe, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 12, 2010
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell TransplantationDavid L Porter, Edwin P Alyea, Joseph H Antin, et al.
American Journal of Hematology|December 15, 2015
A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908)Clive S Zent, Xin Victoria Wang, Rhett P Ketterling, et al.
Leukemia Research|November 4, 2022
Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profilingChezi Ganzel, Zhuoxin Sun, Timour Baslan, et al.
Haematologica|January 26, 2013
The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trialDavid I Marks, Anthony V Moorman, Lucy Chilton, et al.
Pageof 24